Efficacy and safety of entecavir for hepatitis B virus-associated glomerulonephritis with renal insufficiency.
Clin Exp Nephrol
; 27(8): 680-686, 2023 Aug.
Article
en En
| MEDLINE
| ID: mdl-37115381
ABSTRACT
BACKGROUND:
HBV-GN is one of the most common secondary kidney diseases in China. Entecavir is a first-line antiviral therapy in patients with HBV-GN.OBJECTIVE:
This retrospective study explored whether entecavir is effective and safe for the treatment of HBV-GN with renal insufficiency.METHODS:
We screened patients diagnosed with HBV-GN in The Affiliated Hospital of Qingdao University who had elevated serum creatinine levels. Group 1 (30 patients) was given entecavir as antiviral treatment. Group 2 (28 patients) was treated with ARBs. Changes in renal function and the possible influencing factors were observed, with a mean follow-up duration of 36 months.RESULTS:
At the end of follow-up, the elevation in the serum creatinine level and reduction in the eGFR were greater in group 1 than in group 2. The overall renal survival rate, using eGFR < 15 ml/min as the primary renal end point, was 96.7% in group 1 and 67.9% in group 2. Urine protein excretion was decreased in both groups. Treatment with entecavir and the remission of proteinuria were protective factors against renal function impairment, while a lower baseline eGFR was a risk factor for progression to ESRD.CONCLUSIONS:
Entecavir slows the progression of renal function impairment in HBV-GN and exerts a significant renal protective effect.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Hepatitis B Crónica
/
Insuficiencia Renal
/
Glomerulonefritis
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Clin Exp Nephrol
Asunto de la revista:
NEFROLOGIA
Año:
2023
Tipo del documento:
Article
País de afiliación:
China